Immunotherapeutics have transformed cancer outcomes. It is crucial that response patterns seen with them are assessed ...
This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...
The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trialCLARITY is a ...
A small trial enrolled 62 people with RRMS who showed signs of cognitive dysfunction to test the effectiveness of acupuncture ...
BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company, announced today that it has raised nearly $20 million in gross proceeds since January 1, 2025. This funding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback